Licensing AstraZeneca castoff, Biohaven preps PhIII effort in new neurodegenerative indication
Biohaven $BHVN has added another drug off of AstraZeneca’s shelf to its neurology pipeline.
Coming with a package of data from four Phase I and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
